ReviewJournal of military, veteran and family health2023
Psychedelic and nutraceutical interventions as therapeutic strategies for military-related mild traumatic brain injuries.
Review in Journal of military, veteran and family health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Psilocybin restores behavior and 5-HTCell reports. Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mild traumatic brain injury (mTBI), also referred to as concussion, is an acquired brain injury that is common in the military. mTBI results in alterations to brain function that are underpinned by a cascade of neuropathological and neurometabolic events that can result in excitotoxicity, oxidative stress, edema, neuroinflammation, and cell death. To date, traditional pharmaceutical therapies have been used with limited success to treat mTBI, leading to interest in the potential for psychedelic and nutraceutical therapies to alleviate the deleterious pathological sequelae that follow neurotrauma. An accumulating body of evidence supports research into the use of classic psychedelics and nutraceutical interventions for treating mTBI and concussion. This article highlights pre-clinical and clinical studies that show classic psychedelics are promising pharmacological interventions for mTBI because of their potent neuroplastic properties - including synaptogenesis and large-scale re-wiring, anti-inflammatory effects, and modulatory properties - on neural excitation and inhibition. The addition of nutraceutical interventions could also hasten recovery and improve general functioning along the spectrum from mild acute injury to long-term chronic issues (e.g., persistent post-concussive symptoms) and, potentially, to other forms of neurodegenerative disorders after neurotrauma and repetitive head injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.